ArticleJournal of the National Cancer Institute2025
Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Type 2 Diabetes, Glycemic Traits and Overall Cancer Risk: A Large-Scale Prospective Cohort Study.Cancer medicine · 2026Article
- The Association Between Religiosity and Lifelong Cancer Incidence in an Israeli Male Cohort: A Competing Risk Survival Analysis.Epidemiologia (Basel, Switzerland) · 2026Article
- Type 2 diabetes and cancer: A retrospective longitudinal comparative cohort study of disease sequence and comorbidity profiles.PloS one · 2026Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
backgroundDiabetes has been associated with the risk of numerous cancers, but the causal relevance of many of these associations remains unclear.
methodsWe investigated associations between diabetes and risks of 15 cancers using Cox-regression and individual-level data from 2.2 million adults (334 978 incident cancer cases) in 3 prospective cohorts, UK Biobank, Million Women Study, and China Kadoorie Biobank. The potential impact of residual confounding was assessed by examining changes in diabetes-associated log hazard ratios (HRs) after adjustment for key confounders.
resultsIn combined analyses of individual participant data from 3 studies, diabetes was positively associated with the risk of 11 cancers, most notably liver (HR = 2.04, 95% CI = 1.87 to 2.23), pancreas (HR = 1.62, 95% CI = 1.48 to 1.77), and bladder (HR = 1.44, 95% CI = 1.29 to 1.62) cancer. The positive associations of diabetes with cancers of the breast, endometrium, kidney, and esophageal adenocarcinoma were substantially attenuated (>50%) after adjustment for confounders. The risks were similar in UK and Chinese populations except for liver cancer for which the adjusted hazard ratio was greater in UK than Chinese adults (HR = 2.58, 95% CI = 2.28 to 2.92, vs HR = 1.61, 95% CI = 1.43 to 1.83; Phet = 2.5 x 10-6). For liver cancer, the excess risk associated with diabetes increased with increasing body mass index (Ptrend = 2.7 x 10-4) and alcohol intake (Ptrend = .02). Diabetes was inversely associated with incidence of prostate cancer (HR = 0.78, 95% CI = 0.73 to 0.85) but positively associated with mortality (HR = 1.25, 95% CI = 1.00 to 1.55).
conclusionsDiabetes increases the risk of liver, pancreatic, and bladder cancer in UK and Chinese populations. It may also have a lesser effect on stomach, colorectal cancer, and leukemia, but its associations with other cancers could well be explained by confounding and/or other biases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.